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Abstract
Introduction
International guidelines recommend that health care clinicians communicate with
people with MND and their family members about non-invasive ventilation (NIV) and
percutaneous gastrostomy tube (PEG) prior to or at the onset of respiratory symptoms. This
study sought to discover the degree to which these recommendations are followed in
practice.

Methods
Interpretive Description methodology was employed for this study, which was set in
two Australian states. Nineteen clinicians experienced in caring for people with MND, six
relatives of recently deceased people with MND and one person with MND participated in
semi-structured in-depth interviews. Clinicians’ accounts of their NIV and PEG-related
communications were compared to the family member participants’ recollections of their own
discussions with clinicians on these topics. Data were analysed thematically.

Results
Six major themes emerged from data analysis that together capture the factors that
impact practitioner-patient-family communications about NIV and PEGs. Some clinicians
were unaware of MND international guidelines particularly communicating the burdens or
possible withdrawal of NIV or found them challenging to implement. Consequently, family
participants reported that they and their relatives with MND found clinicians’ communication
on these topics inadequate. This led to them ‘topping up’ their knowledge from less
authoritative sources, predominantly the internet.
Discussion
Clinicians’ lack of awareness of the international guidelines and discomfort about
discussing the benefits and burdens of NIV and PEGs means that health care users and
their loved ones are at risk of being unprepared for the consequences of commencing, using
and ceasing NIV. Further research to discover how best to implement the evidence-based
guidance on this topic into practice is warranted.

Keywords: Motor Neuron(e) Disease, amyotrophic lateral sclerosis, palliative Care,
noninvasive ventilation, communication

Introduction
Motor Neurone Disease (MND), the most common form being Amyotrophic Lateral
Sclerosis (ALS), is a progressive neurological condition that adversely affects muscular
control 1, 2. Muscles weaken, causing breathing, communication and swallowing difficulties,
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and ultimately respiratory failure and death. Respiratory failure is often a complication of
respiratory infection secondary to aspiration. The duration of survival from the onset of
symptoms is 20-48 months 3.
The global incidence of MND / ALS was calculated in 2019 as ranging between 0.63.8 per 100 000 person-years, and as proportionally higher in Europe (2.1-3.8 per 100 000
person years) than in Asia (0.8-1.2 per 100 000 person years)4 . This represents an overall
rise in recent years: in 2005 the estimate of the worldwide occurrence was 1.5 – 2 per
100,000 per year 5, with an approximate lifetime risk of developing the disease of 1 in 800 6,
and a subsequent systematic review of European literature suggested this had increased to
2.08 per 100,000 four years later7.
In June 2019 more than 2,000 people were known to have MND in Australia (60%
male and 40% female). At that time two people were diagnosed with MND and two people
died from MND in Australia each day. The prevalence of MND in 2015 was 8.7 per 100,000
people or 1 per 11,434 Australians. The global increase in cases noted earlier appears to
include Australia: In 2016, 791 persons died from MND in Australia compared to 592 in 2001
8
MND is a progressive, terminal neurological disease for which there is no known cure and
no effective treatment 8.
The disease presents a number of care-related challenges, beginning with it being
extremely difficult to diagnose because symptoms may be isolated and unexplained 9 and
compounded by the progressive loss of limb use and the ability to speak, swallow and
breathe, all while the person’s mind and senses usually remain intact. As respiratory
muscles become progressively affected, non-invasive ventilation (NIV) is usually offered to
alleviate distressing respiratory symptoms. There is general agreement that in addition to
symptom relief, NIV can improve survival, particularly if there is no bulbar involvement 9, 10.
The consideration of a feeding tube via Percutaneous Endoscopic Gastrostomy (PEG) to
maintain nutrition and hydration is recommended prior to the onset of respiratory symptoms
due to a potential increase in respiratory complications with later insertion 9. However, as
PEG tubes offer little or no extension of life, have minimal effect on relieving aspiration and
can be uncomfortable, some people with MND refuse PEGs 11.
The seminal clinical care resource for diagnosis and care of people with MND is the
evidence-based guidance published by the UK National Institute for Health and Care
Excellence (NICE) in 2016. These guidelines provide clear recommendations for recognition
of the disease, referral to specialist services, how information and support should be
provided at diagnosis, determining cognitive capacity, care planning care that takes account
of various prognostic factors as well as psychological and social care needs, how care
should be organised, end of life planning, and symptom management (including key points
to include in PEG and NIV-related conversations). Early discussion of the implications,
benefits and burdens of both NIV and PEG tubes is recommended in this and other
international consensus evidence-based guidelines 9, 12, however the extent to which this
guidance has translated into practice is underreported 13.
Research into the experiences of people with MND and their families frequently
suggests that clinician communication is generally inadequate, particularly when delivering
the diagnosis 14-16. For people with MND, deteriorating health and increasing symptoms
mean that treatment decisions involving potential life-sustaining technologies are often faced
early in the person’s clinical care. Thus, accurate information about the benefits and burdens
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as well as the life extension limitations of such treatments needs to be communicated early
and revisited as the disease progresses9. A potential complication lies in how MND is
perceived and characterised by clinicians. The variants of MND and the sometimes
unpredictable timing of progression of the disease can mean that the point at which a person
is perceived as having a chronic and terminal disease becomes difficult to predict. The point
at which chronic illness becomes defined as terminal may confuse the timing of support
required by the person with MND and their caregivers17. In addition, multiple health
professionals and several different service organisations may be involved with the person
with MND from diagnosis, which has the potential for missed communications, confusion and
conflicting messages.
The problem this study thus sought to address was that it is unknown whether
clinicians implement best evidence-based guidance in their communications about end-of-life
treatment choices with people with MND and their family members. The objectives of the
study were to describe clinician communication surrounding NIV including end-of-life
choices, to understand how clinicians check the level of understanding among patients and
family members of the benefits, burdens and potential of NIV withdrawal prior to NIV
commencement, and to compare the content, process and outcomes of NIV communication
as described by clinicians and families of people with MND within this study against the
currently available recommendations relating to commencement and withdrawal of NIV and
related end-of-life care options. To that end, the overarching research question we sought to
answer was ‘How effective are clinicians’ efforts in facilitating patients’ and family members’
understanding of the options regarding PEG and NIV, and of the value and possible burdens
of those treatments?

Methods
Design. This study was conducted using Interpretive Description (ID) methodology18, 19. ID
was developed principally as a process for obtaining knowledge within the context of clinical
events to elicit change9 and incorporates aspects from grounded theory and
ethnomethodology in its approach to purposive data collection10. The ID process and
outcome enables light to be thrown on a collection of expressed truths to inform a practical
change, and for this reason it was selected as the most appropriate approach for
investigating communication between clinicians, patients and family members. The purpose
of the study was to answer the following research question: ‘How effective are clinicians’
efforts in facilitating patients’ and family members’ understanding of the options regarding
PEG and NIV, and of the value and dis-benefits of those treatments?’ and to address there
related objectives (to describe clinician communication surrounding NIV including end-of-life
choices, to understand how clinicians check the level of understanding among patients and
family members of the benefits, burdens and potential of NIV withdrawal prior to NIV
commencement, and to compare the content, process and outcomes of NIV communication
as described by clinicians and families of people with MND within this study against the
currently available recommendations relating to commencement and withdrawal of NIV and
related end-of-life care options).
Setting
The study was set in two Australian states: Western Australia and New South Wales.
Sample
4

Purposeful sampling 18 was employed to ensure the participation of informants with
knowledge of the phenomenon of interest. The sample included healthcare clinicians
involved with the respiratory care of MND, NIV initiation, NIV withdrawal and end-of-life care,
and relatives of deceased people with MND who had used NIV. Uninvited, one person with
MND who was using NIV requested inclusion in order to share experiences. Therefore, one
interview was conducted with a person with MND. These data were used to illuminate and
contextualise the two primary data sets.
Additional participant characteristics are provided in Tables 1 and 2.
Table 1. Family Participant Demographics
Family
Participants
F 1/2

Health knowledge
and/or health
information from
internet
No

Regional, rural
or remote

Primary clinical
responsibility
for overall care

Regional/rural

Unclear: GP and
neurologist
Neurologist and
GP
GP

Part of
structured MDT
No

F3

Yes

Regional

F4

No

Rural

F5

Yes

Remote

GP

No

F6

Yes

Rural

GP

No

P1

No

Regional

Neurologist

Yes
No

Intermittently

Note: General Practitioner (GP), Multidisciplinary team (MDT)

Table 2. Clinician Participant Demographics
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Years (y) of MND experience
and % of workload dedicated
to caring for people with
MND
10+ y
Varies

Involved with
NIV withdrawal
discussions

Regional, rural
or remote

Yes

Regional and
rural

10 y
Varies

Yes

Regional

Palliative Care Specialist
(Medical Practitioner)
Respiratory Specialist
(Medical Practitioner)

17 y
Varies
12 y
Varies

Yes

Regional

Sometimes

Regional and
rural

C5

Respiratory Specialist
(Medical Practitioner)

6y
75%

Yes

Regional and
rural

C6

Neurological Nurse

C7

Neurological Nurse

4.5 y
Intermittent
8y
Intermittent

C8

Palliative Care Nurse

C9

Palliative Care Nurse

C10

Palliative Care Nurse

C11
C12

Respiratory Specialist
(Medical Practitioner)
Physiotherapist

C13

Clinician

C1
C2
C3
C4

Specialty
Palliative Care
Consultant (Medical
Practitioner)
Palliative Care Specialist
(Medical Practitioner)

16 y
Intermittent
14 y
Intermittent
5y
Intermittent
10 y

No
Indirectly; when
patient requires
information
Yes

Regional and
rural
Regional and
rural
Regional

Yes

Regional

Yes

Regional and
rural
Regional and
rural
Regional

Yes

5% of annual work

Yes

Social Worker

approx. 30 MND pts ongoing

Sometimes

C14

MND Clinical Nurse
Specialist

14 y
Ongoing

Yes

C15

Gastroenterologist
(Medical Practitioner)

Sees 2-4 people with MND
monthly

No

C16

MND Clinical Nurse
Consultant

15 y
Ongoing

Yes

C17

Respiratory Clinical
Nurse Consultant

22 y
Varies

Yes

C18

Rehabilitation MND
Specialist (Medical
Practitioner)

16 y
approx. 30 MND/year

No

C19

Palliative Care
Consultant (Medical
Practitioner)

11 y
approx. 30 MND/year

Yes

Regional
Regional
Regional
Regional
Regional
Regional

Regional

Participant recruitment
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Clinician and family participants with experience of MND care were invited to
participate through palliative care services, hospitals, support organisations and specialist
palliative centres care via email, letter, newsletter or face-to-face invitation by staff members.
An information sheet and consent form were sent to those who expressed interest. All
participants who requested the information sheet subsequently agreed to be interviewed. No
participant who consented to be interviewed later withdrew.
Data collection
Data were obtained through single audio-recorded one-to-one semi-structured
interviews with individuals that were conducted by [the first author], who is both a senior
palliative care nurse and researcher with extensive training and experience in interviewing,
communication and information gathering. All clinician interviews took place in a private
room within their workplace or via videoconference or telephone. All family participants
chose home interviews. No family participant was known to the interviewer prior to
recruitment into the study.
Clinician participants were asked open-ended questions about what/when they
communicated to people with MND and their families about NIV, its limitations, its benefits
and its burdens. They were asked how they communicated the withdrawal of NIV, early
palliative care referral, end-of-life choices, Advance Health Directives (AHD) and PEGs.
Further, clinicians were asked how they ascertained understanding of the information by the
person with MND and their families.
Family member participants and the person with MND were asked to consider two
points in time: first when respiratory symptoms commenced and second when it became
necessary to consider end-of-life care options. They were asked what they recalled at each
time-point about the communication about PEG and NIV, and NIV withdrawal. They were
also asked what they understood about the need for early palliative care referral, benefits
and possible burdens of NIV and PEGs and whether AHDs were encouraged by clinicians.
All interviews were terminated when the participant indicated they had nothing further to add,
and each participant received a copy of their transcribed interview and all approved its
inclusion in data analysis 20. Data collection ceased when saturation of themes was
achieved.
Data analysis
Participant de-identification by the principal investigator occurred prior to the
interview transcription, through a pseudonym allocation (e.g. P1). The initial phase of the
data analysis identified emergent words and phrases (‘codes’) that related to the research
questions. The NVivo 11™ software package was used to assist the process of coding the
developing sub-themes and themes (Figure 1). When no new data were provided, saturation
was assumed, and no further interviews occurred.
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Figure 1. Example of the Coding Tree

Trustworthiness
Trustworthiness of the research was assured primarily by designing interview
questions which encouraged participants to describe conversations they had with clinicians
surrounding the initiation, use and ultimate removal of NIV in patients with MND 20. Several
additional measures were implemented to ensure trustworthiness of the study. First, the
transcribed interviews were returned to the participants for validation and approval for use in
the data analysis20-22. Second, all interviews were analysed by the first author, and three
were also analysed independently by author two; similar themes were derived by both. Third,
themes developed from analysis were discussed by all members of the research team and
consensus reached. Fourth, an audit trail that includes interview transcripts, analysis of data,
process notes, notes about difficulties encountered, personal notes and draft documents
have been kept 21-23.

Ethical considerations
Approval to conduct the study was obtained from the Human Research Ethics
Committees at Edith Cowan University (ECUHREC Number 12099), Silver Chain Hospice
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Nursing WA, two St John of God Hospital sites in WA and the Neurological Council of WA.
Participants were offered the opportunity to ask questions and informed of their right to
withdraw at any time until data analysis. Information on counselling services was provided in
case of distress following the discussion. Participants who agreed to be interviewed and
audio-recorded signed a consent form.

Results
Nineteen clinician participants were interviewed, eight of whom had experience of
early respiratory symptoms in people with MND and ten of palliative or end-of-life care. Six
family member participants and one person with MND were interviewed, all from Western
Australia. Twenty nine hours and thirty minutes of data were collected from which six major
themes emerged when data analysed: ‘Experience of clinicians with NIV withdrawal’;
‘Timing and content of communication about the benefits and burdens of NIV, PEGs and
end-of-life choices’; ‘Time allocated for communicating and discussing end-of-life choices’;
‘Early referral to palliative care and family understanding of palliative care’; ‘Communication
within a multi-disciplinary team’; and ‘Patient and family communication and understanding‘.

Experience of clinicians with NIV withdrawal
All the clinician participants interviewed had many years of experience of
communicating with patients and relatives about end-of-life decisions (4.5-22 years), with 12
of the 19 clinicians having had at least 10 years in practice. Significant practice experience
did not appear to make discussions about NIV withdrawal easier or more likely for clinician
participants, and despite their knowledge of the best practice evidence, many clinicians
reported difficulty giving ‘good’ information when there was uncertainty about the
deterioration trajectory.
The complex challenges of deciding the exact protocol and timing for NIV withdrawal,
assessing family readiness for the information and maintaining comfort until death, were
described by several clinicians as particularly dreaded. Participant C11, a medical
practitioner specialising in respiratory care, exemplified this in the following quote:
[it’s] bloody awful, because – the when, how, pharmacotherapy, you know. What do you do?
Do you necessarily withdraw NIV or do you let people die on NIV? … [And] I suspect it’s
enormously difficult from the family’s point of view unless the conversations leading up to it
have been really good and really clear.
C19 (palliative care consultant): I think one of the barriers is sensitivity or worrying that
that’s – even having that conversation is going to upset the patient or the family.
One of the most noted barriers clinician participants experienced in this regard was patient
denial:
C4 (respiratory specialist): [Often you hear] “Oh, I just don’t want to think about it. I don’t
want to know.” So that can be a bit of a challenge that their defence mechanism, their way
of coping is one of, “That’s later on,” denial.
Family members’ experiences of this uncertainty and vagueness in clinicians about
withdrawal of NIV meant that they then didn’t have enough information to contribute an
9

opinion about care decisions. F5, who self-reported as having high health literacy and
knowing what questions to ask, said:
Because in these appointments you – particularly with a neurologist who gives you an
overall reading on how the whole thing’s going, if you don’t ask questions, and you’re not an
assertive sort of person, sometimes I think you could walk out missing a lot, do you know
what I mean?
In some cases, no-one ever discussed NIV withdrawal with patients and families, and the
impact of this can have profoundly devastating and long-lasting effects:
F1 (family): I think now, I would have opted for [NIV withdrawal] because Mum was so
uncomfortable and so suffering that I would have opted to say, “Let’s, you know, ditch that…”
– and I think now Dad would have taken that option. But from what we knew, and what we –
while we were going through it, I don’t think we would have done any different to what we did
do. But do you know what I mean, hindsight’s a wonderful thing . . .
I regret – and you can use that as a quote if you want – but I regret the last three nights that
mum had at home. It was awful for her, for dad, for me. It was just – still burned in my
memory, and it’s hard to sort of go away.’

Timing and content of communication about the benefits and burdens of NIV,
PEGs and end-of-life choices
Many of the clinician participants reported that the timing for raising the topic of the end of
life and NIV withdrawal with patients and family members challenging. There was also
confusion among clinicians about who was responsible for these communications, and
concern that patients might not be prepared for them. Most of the specialist clinicians
interviewed said they tried to ascertain how much the person with MND and their family
knew about the course of the disease and tailored the communication content accordingly.

C4 (respiratory specialist): I mean, you’re talking about end-of-life issues, which
many health practitioners are uncomfortable talking about. And then I would think 20
to 40 to 50 per cent of patients will tend to say, “Well, we don’t want to talk about
that. We’ll think about it when the time comes.” So even though you may have the
best intentions of trying to have all this out in the open and discussed and
documented, it’s not always the case that the patients wish to discuss it.
C2 (palliative care specialist): We’re palliative care doctors. We like to think that we’re
good at communicating, but I think, I acknowledge, that often families need to hear things
multiple times.
Further, most clinician interviewees spoke about being sensitive to the contradictory nature
of the complex information relating to withdrawal of NIV and what this means to patients and
families:
C12 (physiotherapist): You’re offering them something that potentially may treat their
symptoms, but then at the same time saying, “Oh, by the way, you know, let’s also talk
about, you know, end of life as well.”
C19 (palliative care consultant): I guess the pros is a very transparent discussion, isn’t it,
that you’re actually, at the time of putting the – sorry, of starting the machine, the NIV, you’re
also talking about the possibility of withdrawal. I can see the merit of that. I guess on the
10

other hand – I’m just thinking of the emotional dimension of that, and I guess that may – I’d
have to think of the sensitivity of that conversation at that time.
C14 (MND clinical nurse specialist): It’s a conversation that we dread, I think, to remove it,
because the breathing is so essential to stay alive. And there’s no good or there’s no best
timing for it.
Compounding clinicians’ uncertainty about the right time for these discussions, many
recognise the preservation of hope can underlie a family’s wish to avoid discussing the end
of life. The following describes the experience of how one clinician dealt with it:
F3 (family): And then when [the person with MND] was, you know, eventually diagnosed,
we – by that stage we’d been reading up on best practice and, you know, we knew all about
the multi-disciplinary team approach, etcetera. And [the health care professional’s] response
was, “Oh, you’re not going to need [end of life care] for a long, long time. And don’t talk to
[patient and carer support organisation] - they’re way too negative. I’ll see you in a year.”

Time allocated for communicating and discussing end-of-life choices
Insufficient time for these conversations was reported by the majority of the clinicians
interviewed for a range of reasons, as participant C2 (palliative care consultant) said:
Time, you know. We’re all very time poor, and these conversations take time, need to be revisited, the patient’s cognitive ability, family issues. You know, conflict within a family. All
sorts of things come into play.
Participant C13 (social worker) elaborated further on the complicating issue of patients’
deteriorating cognitive ability:
What concerns me sometimes with that [frontotemporal dementia] is that they [person with
MND] don’t have a deeper understanding of the situation [as they would] if they didn’t have
the FT [frontotemporal] [issues] happening, and it impacts on the carers, and that’s my
concern
With limited time for communication, clinicians described prioritising explanations about NIVrelated technicalities.
C11 (respiratory specialist): [I focus on] how to set up the mask, how to set up the
machine, how to plug it in, what to do if it leaks, what to do if they get rain out, what to do if
they get this, that and something else… a lot of the attention can be focused on the sort of
practicality of the machine, and the sort of softer, more difficult conversations often get a little
bit left to the side.
The potential impact of this on patients and families, was that they may not have
meaningful input to care:
F6 (family): So, you know, some health professionals – I think periods of silence to listen to
the client are needed without the health professional thinking, “I’ve got to tell them X, Y,
Z…”.”
Patient and/or family member reluctance or lack of readiness to ‘go there’ was also
cited by clinical respondents as a barrier to having these conversations:
C11 (respiratory specialist): There are some people that are willing to engage in this, and
then there are other people where you can’t get them to engage in discussions about end-of11

life care. And so, my goal is to do it early and to do it often until I feel like the patient and I,
and family and I, are on the same page. But it’s sometimes, in the real practical world, more
difficult than that.

Early referral to palliative care and family understanding of palliative care
Many clinicians are reluctant to make or accept an early referral for people with MND
to palliative care despite acknowledging this to be best practice, and sometimes the referral
is declined by patients and/or family members.
C4 (respiratory specialist): …ideally [I refer] all patients very early on, close to the time of
diagnosis. For various reasons some patients don’t want that.
C2 (palliative care consultant): To be honest, most of my [MND] patients are referred very
late, and we look after them for their end-of-life care.
C16 (MND nurse consultant): …some pall. care teams are quite open to that [early
intervention], but some pall. care teams have this weird definition period that they will not
accept the patient until they have three months or less to live.
F5 (family): She’s a specialist. And she said, “Now, I’ve got a letter here from your GP
saying that you’re in denial about all this.” And we said, “We’re definitely not in denial about
what’s happening to us. We’re just in denial that we need to see a palliative care team so
early. That word ‘palliative’ over-shone whatever they were saying to us”
F3 (family): [Palliative care] was discussed, and because … we now know that palliative
care is really the only thing that you can do with motor neurone disease...but at that stage
we were thinking “end of life”?? … and we were getting a bit paranoid.

Communication within a multi-disciplinary team
Despite the recommendation that a multi-disciplinary team (MDT) approach is used,
poor experiences of this were evident.
C1 (palliative care consultant): I think my …fear is you can get so many teams of people
involved. You’ve got specialist palliative care, GP and primary care, respiratory care,
gastroenterologist who’s been involved with the PEG, the rehabilitation team, a neurologist
who’s saying – you know, and the possibilities of confusion and misinformation are
enormous… I was going to say warfare [can occur].
Further, the health professionals interviewed described suboptimal communication between
professionals:
C4 (respiratory specialist): Look, I don’t think [communication between healthcare
professionals is] particularly ideal at all. The communication we have is by letter, very
occasionally a phone call. I don’t get a lot of – I mean, I write letters [to other clinicians], and
I think I’m communicating, but I don’t feel I get a lot of feedback, unless there’s a big
problem.
In some cases, this was because there was no MDT:
12

C19 (palliative care consultant): Now, the interesting thing in the city is that not
everywhere has a multi-disciplinary team. So, it’s a bit of a patchwork quilt, and indeed
would be the whole of Australia a patchwork quilt.
Gaps in communication within MDTs were found to be confusing for patients and families
who needed to repeat the same information:
F1 (family): We’d been to a few speechies [speech therapist] and dietitians, which Dad was
getting confused about. So, I sort of explained to them that the dietitian was about the
nutrients; the speechy was about … how to swallow, and the muscles in the neck. And Dad
said, “We’re saying the same things to the same people.”

Patient and family understanding
Denial and lack of understanding by some people with MND and their families about
how quickly the disease can progress was expressed as a communication barrier by some
clinician participants. Others noted that some people with MND and their families had been
given little or conflicting information about the disease prior to seeing them.
C2 (palliative care consultant): Some of them have clearly been told but don’t necessarily
want to hear, understand or acknowledge, and some clearly have [had] very limited
explanation.
C1 (palliative care consultant): There was one person who was told it [MND] would – he’d
known patients where it had burnt out after a few years and not progressed. So those
patients – you know, it can be difficult because they may get mixed messages – different
messages when they see a neurologist in a clinic who says, “Oh, you shouldn’t be thinking
about a gastrostomy” when we’re already starting to talk about gastrostomy.
Several of the health professionals in our study put forward that advice to people with
MND regarding PEGs was unclear.
C3 (palliative care specialist): Just touching on PEG tubes again, I think they’re often sold
to people as more of a solution than they are, and I don’t think the difficulties of PEG tubes
are adequately communicated… So, I think, you know, they’re kind of seen as an easy
option when someone can’t swallow, and the reality of dealing with the other side of it isn’t
always discussed as well.
As with NIV, some clinician participants felt the decision about PEG tube insertion required a
degree of understanding that some patients and families did not have:
C15 (gastroenterologist): Understanding the medical complexities of PEG tube insertion
needs a fair degree of health literacy and that can sometimes be a barrier.
Discussion
This study sought to answer one overarching research question and fulfil three
objectives, and those aims were achieved. Four key learnings emerged from this study. The
first was that neither extensive practice experience nor knowledge of best practice evidence
appear to make discussions about NIV withdrawal with people with MND and their families
13

easier or more likely for clinicians. The second was that knowing when the time is right to
raise the topic of the end of life and NIV withdrawal with people with MND and family
members is challenging for clinicians and once clinicians do commit to broaching these
subjects, having adequate time for these very sensitive conversations is difficult to find. The
third was that knowing who is responsible for initiating and continuing the conversation is not
well understood by clinicians. Fourth was that family participants reported, likely as a result
of all of the above, that they and their relatives with MND found clinicians’ communication on
these topics to be inadequate. This led families to ‘top up’ their knowledge from less
authoritative sources. The family participants in this study admitted to seeking clarifying
information from the internet.

Clinician avoidance of difficult discussions seen in this research has been previously
identified in MND 9, 13, 16, 24-26. International guidelines recommend early involvement of
specialist palliative care and communication of end-of-life options 9, 12. This study has found
clinicians make efforts to deliver end-of-life options, but not necessarily as the guidelines
recommend 9, 12. The assumption that people will turn to the Internet to address their
questions and fears may lessen the urgency clinicians feel to initiate such sensitive
communication.
The clinicians stated that time limitations affected their ability to comprehensively
communicate the progressive nature of MND, the issues related to NIV and PEGs, treatment
and end-of-life choices. It also limited their ability to ensure patient understanding of potential
NIV withdrawal. Whilst all the bereaved families recognised the variability of the disease
progression, all wished an idea of remaining life expectancy could have be given at symptom
onset to enable some life planning 27, 28. The proposal to initiate NIV is an accepted trigger
point at which clear discussion should occur. These discussions are often delayed by
clinicians’ perception of a lack of patient or family readiness to engage in them and clinicians
may not acknowledge the necessity of these discussions when the patient’s condition
deteriorates29. Most of the clinicians in this research focussed on the positives surrounding
symptom control rather than prolonging suffering by surviving longer.
Although the most recent guidelines recommend referral to palliative care soon after
diagnosis, this study found that in practice this did not usually occur, agreeing with an
extensive systematic review 13. Both clinician and family participants agreed that determining
the optimal time for referral to a palliative care service is complex 16, 30, 31. The palliative care
specialists stated that they often had to clearly point out and belatedly discuss end-of-life
options not discussed earlier 14, 27, 32, 33. Whilst some clinicians had minimal knowledge of the
MND guidelines, others stated that the recommendations relating to early end-of-life
communication were emotionally inappropriate. The bereaved families stated that early
referral to a palliative care service was overwhelming, equating palliative with death, and it
was apparent that the capabilities of palliative care had not been communicated or
understood. Early symptom control communication enables patients and families time for
informed discussion, to plan and prepare, and may prevent unwanted symptom control
interventions such as NIV, gastrostomy tubes and the potential of invasive ventilation. Other
studies tend to support these conclusions 31, 34. Several studies show that people with MND
would like as much information as is available and the opportunity to discuss treatment
options, believing that doctors should initiate such conversations 35, 36.
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Anecdotally, experience with communicating end-of-life choices to palliative care
patients generally enhances a clinician’s ability to sensitively discuss options of care36.
Clinical experience in palliative care and respiratory medicine was, therefore, anticipated to
facilitate the difficult discussions soon after diagnosis. In this study, however, the experience
of having prior involvement with withdrawal of NIV, an important aspect of MND, did not
always make such communication easier for the clinicians37.
The provision of structured multidisciplinary teams (MDT) was patchy within the area
studied. Families and clinicians identified that communication barriers were pronounced
when there is no structured MDT or single health professional responsible for patient care.
Families with poor health literacy or knowledge of the health care systems lacked the skills
or confidence to ask relevant questions relating to end-of-life and symptom control choices.
The families and people with MND were aware time was not on their side and resented
intrusion from many services and considered repetition of information to multiple people
within an MDT as time-consuming, fatiguing and overwhelming 25, 38.
Prolonging life and hope were considered important to the clinicians and influenced
their decisions to discuss NIV withdrawal and end-of-life choices. None of the bereaved
family participants recalled discussion about the potential of prolonging life in the context of
possible suffering 32, 39, 40. Reflecting, some bereaved family participants said that their family
member did suffer from not understanding that the NIV could be withdrawn.
There are limitations to this study, including only one perspective of people with MND
was included. Nonetheless, our questions about how communication about PEG and NIV is
delivered as recommended by guidelines, how effective clinicians’ efforts are in facilitating
patients’ and family members’ understanding of PEG and NIV, and of the value and disbenefits of those treatments were answered to some degree: we discovered that
communications around end-of-life care options per se, and PEG and NIV in particular, are
complicated by myriad of considerations and challenges that are not accounted for in the
evidence-based guidance.
How effective are clinicians’ efforts in facilitating patients’ and family members’
understanding of the options regarding PEG and NIV, and of the value and possible burdens
of those treatments? This research found the clinician preference for preservation of hope,
lack of time for in-depth communication and the stigma of palliative care were all barriers to
family understanding. The results will be of interest to all health care clinicians involved in
the care of those diagnosed with a life-limiting disease for whom respiratory support may be
helpful and their families, and to policy makers. The relevance of the study findings for
patients and for carers is that the health service user perspectives reported can be used to
inform practice improvements and further research, which is warranted to effectively capture
the barriers to effective, timely and comprehensive end of life treatment options. Recent endof-life and clinical palliative care literature suggests that NIV is being increasingly employed
as a palliating intervention for dyspnoea beyond MND to other progressive respiratory
diseases such as lung cancer and emphysema 41. Understanding the gaps in
communication, when discussions occur, how well the necessary information is
communicated and comprehended by people with MND and their families is, therefore,
becoming increasingly relevant to other diseases41, 42. The views of clinicians working with
patients with chronic obstructive pulmonary disease and interstitial lung disease have been
recently published and this adds the views of those providing MND care 43.
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